1. Comparison of humoral and cellular immune responses in hematologic diseases following completed vaccination protocol with BBIBP-CorV, or AZD1222, or BNT162b2 vaccines against SARS-CoV-2
- Author
-
Enikő Szabó, Szabolcs Modok, Benedek Rónaszéki, Anna Faragó, Nikolett Gémes, Lajos I. Nagy, László Hackler, Katalin Farkas, Patrícia Neuperger, József Á. Balog, Attila Balog, László G. Puskás, and Gabor J. Szebeni
- Subjects
hematology diseases ,SARS-CoV-2 vaccination ,BBIBP-CorV ,AZD1222 ,BNT162b2 ,COVID-19 ,Medicine (General) ,R5-920 - Abstract
BackgroundVaccination has proven the potential to control the COVID-19 pandemic worldwide. Although recent evidence suggests a poor humoral response against SARS-CoV-2 in vaccinated hematological disease (HD) patients, data on vaccination in these patients is limited with the comparison of mRNA-based, vector-based or inactivated virus-based vaccines.MethodsForty-nine HD patients and 46 healthy controls (HCs) were enrolled who received two-doses complete vaccination with BNT162b2, or AZD1222, or BBIBP-CorV, respectively. The antibodies reactive to the receptor binding domain of spike protein of SARS-CoV-2 were assayed by Siemens ADVIA Centaur assay. The reactive cellular immunity was assayed by flow cytometry. The PBMCs were reactivated with SARS-CoV-2 antigens and the production of activation-induced markers (TNF-α, IFN-γ, CD40L) was measured in CD4+ or CD8+ T-cells ex vivo.ResultsThe anti-RBD IgG level was the highest upon BNT162b2 vaccination in HDs (1264 BAU/mL) vs. HCs (1325 BAU/mL) among the studied groups. The BBIBP-CorV vaccination in HDs (339.8 BAU/mL ***p
- Published
- 2023
- Full Text
- View/download PDF